<DOC>
	<DOCNO>NCT00640016</DOCNO>
	<brief_summary>To investigate effect CAT-354 airway hyper-responsiveness ( AHR ) uncontrolled asthma .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety , Tolerability CAT-354 Subjects With Asthma</brief_title>
	<detailed_description>This randomize , stratify , double-blind , placebo-controlled , multicenter , multinational study subject uncontrolled asthma despite optimal treatment . Following confirmation eligibility , subject randomly assign Day 0 , 1 4 dose group 1 mg/kg CAT-354 , 5 mg/kg CAT-354 , 10 mg/kg CAT Placebo match dose CAT-354 . Doses assign treatment administer three occasion 28 day apart . Subjects assess efficacy , include airway hyper-responsiveness ( AHR ) , safety , pharmacokinetic , pharmacodynamics immunogenicity Day 84 post-first dose .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Signed date write informed consent obtain prior study related procedure take place Women either infertile ( example [ e.g . ] , hysterectomized , sterile postmenopausal amenorrhea least 1 year duration ) practice acceptable form birth control Uncontrolled ( refractory ) asthma despite treatment minimum dose 800 microgram ( mcg ) beclomethasonedipropionate equivalent inhale corticosteroid per day plus 1 additional controller , , longacting betaagonist , leukotriene antagonist theophylline . Oral corticosteroid ( parenteral ) additional treatment dose acceptable A forced expiratory volume 1 second ( FEV1 ) acceptable airway hyperresponsiveness ( AHR ) challenge test ( great 60 percent predict normal ) challenge day A provocative concentration methacholine cause 20 percent fall FEV1 ( PC20 ) less 4 milligram per milliliter ( mg/mL ) Aged 1880 year A 12lead electrocardiogram ( ECG ) noclinically significant abnormality Clinical chemistry , hematology urinalysis result within laboratory reference range deem clinically significant Investigator Body weight less 130 kilogram ( kg ) No clinically significant abnormality history clinical examination Able comply requirement protocol . Experienced severe exacerbation within 28 day precede Day 28/14 Day 0 Onset uncontrolled seasonal allergy symptom within 28 day precede Day 28/14 Day 0 Subjects history allergic rhinitis , seasonal allergy esophagitis must optimally control remain stable treatment regimen study Participation another study within 5 halflives 3 month start study , whichever long Lower respiratory tract infection within 6 week Day 28/14 Day 0 Current smoker exsmokers great 10 packyears Blood donation ( 550 mL ) previous 2 month Excessive intake alcohol ( judged Investigator ) evidence drug solvent abuse Subjects physiciandiagnosis significant lung disease , include primary diagnosis chronic obstructive pulmonary disease bronchiectasis , lung cancer , sarcoidosis , tuberculosis , pulmonary fibrosis cystic fibrosis Concurrent medication Day 28/14 Day 0 ( Screening visit ) duration study prohibit medication Significant , uncontrolled disease include serious psychological disorder , chronic renal failure , uncontrolled hypertension systolic blood pressure great 200 millimeter mercury ( mmHg ) , diastolic blood pressure great 100 mmHg , heart disease , psoriasis require treatment subject heart attack stroke within 3 month precede Day 28/14 Day 0 , know aneurysm Onset uncontrolled seasonal allergy symptom within 28 day precede Day 28/14 Day 0 Subjects history allergic rhinitis , seasonal allergy esophagitis must optimally control remain stable treatment regimen study Any factor , opinion Investigator , would jeopardize evaluation safety associate poor adherence protocol ( , inability complete study diary , perform peak expiratory flow ( PEF ) measurement ) The subject 's primary care physician recommend subject take part study Known hypersensitivity CAT354 component , challenge agent use study related drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>CAT-354</keyword>
	<keyword>Tralokinumab</keyword>
</DOC>